Royal Bank of Canada’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-924
| Closed | -$20K | – | 7736 |
|
|
2024
Q1 | $20K | Sell |
924
-33,595
| -97% | -$402K | ﹤0.01% | 5931 |
|
|
2023
Q4 | $332K | Buy |
34,519
+30,315
| +721% | +$147K | ﹤0.01% | 4642 |
|
|
2023
Q3 | $11K | Buy |
4,204
+2,365
| +129% | +$7.58K | ﹤0.01% | 6402 |
|
|
2023
Q2 | $9K | Sell |
1,839
-364
| -17% | -$1.57K | ﹤0.01% | 6518 |
|
|
2023
Q1 | $8K | Buy |
2,203
+1,353
| +159% | +$5.33K | ﹤0.01% | 6435 |
|
|
2022
Q4 | $3K | Hold |
850
| – | – | ﹤0.01% | 6886 |
|
|
2022
Q3 | $3K | Hold |
850
| – | – | ﹤0.01% | 6946 |
|
|
2022
Q2 | $2K | Hold |
850
| – | – | ﹤0.01% | 7024 |
|
|
2022
Q1 | $7K | Hold |
850
| – | – | ﹤0.01% | 7144 |
|
|
2021
Q4 | $4K | Sell |
850
-1,500
| -64% | -$9.36K | ﹤0.01% | 7298 |
|
|
2021
Q3 | $19K | Buy |
2,350
+1,200
| +104% | +$10.1K | ﹤0.01% | 6730 |
|
|
2021
Q2 | $9K | Buy |
1,150
+837
| +267% | +$7.2K | ﹤0.01% | 6924 |
|
|
2021
Q1 | $3K | Buy |
313
+13
| +4% | +$152 | ﹤0.01% | 7187 |
|
|
2020
Q4 | $4K | Hold |
300
| – | – | ﹤0.01% | 6760 |
|
|
2020
Q3 | $4K | Hold |
300
| – | – | ﹤0.01% | 6200 |
|
|
2020
Q2 | $5K | Buy |
+300
| New | +$5.22K | ﹤0.01% | 6062 |
|
Royal Bank of Canada's FUSN Position: Q2 2024 in Review
Royal Bank of Canada sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q2 2024, closing a stake of 924 shares — an estimated $20K sold.
Royal Bank of Canada first reported a position in FUSN in Q2 2020 and held it in 16 quarters. The position peaked at $332K in Q4 2023. 0 funds tracked by Wall St. Rank hold FUSN as of Q2 2024.
- Royal Bank of Canada reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q2 2024 after selling out during the quarter.
- Royal Bank of Canada sold 924 Fusion Pharmaceuticals Inc. Common Shares shares in Q2 2024, an estimated $20K.
- Royal Bank of Canada first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q2 2020 and held it in 16 quarters.
- Royal Bank of Canada's Fusion Pharmaceuticals Inc. Common Shares position peaked at $332K in Q4 2023.
- 0 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q2 2024.
Based on Royal Bank of Canada's 13F filing for Q2 2024, filed 14 Aug 2024.